Astrazeneca Plc's Customers Performance

Name: Astrazeneca Plc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

AZN

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


AZN's Source of Revenues		During the corresponding time, Astrazeneca Plc recorded a revenue increase by 8.63 % year on year, While revenue at the Astrazeneca Plc's corporate clients • List of AZN Customers

for the same period Astrazeneca Plc recorded revenue increase by 8.63 % year on year,

• List of AZN Customers

Astrazeneca Plc's Business Units


US	40.81 %	of total Revenue
Emerging Markets	25.63 %	of total Revenue
Europe	20.47 %	of total Revenue
Rest of World	8.6 %	of total Revenue
Total Oncology	40.34 %	of total Revenue
Total Oncology US	19.05 %	of total Revenue
Total Oncology Emerging Markets	9.11 %	of total Revenue
Total Oncology Europe	8.31 %	of total Revenue
Total Oncology Rest of World	3.88 %	of total Revenue
Tagrisso	12.35 %	of total Revenue
Tagrisso US	5.22 %	of total Revenue
Tagrisso Emerging Markets	3.36 %	of total Revenue
Tagrisso Europe	2.42 %	of total Revenue
Tagrisso Rest of World	1.36 %	of total Revenue
Imfinzi	10.32 %	of total Revenue
Imfinzi US	5.97 %	of total Revenue
Imfinzi Emerging Markets	1.09 %	of total Revenue
Imfinzi Europe	2.11 %	of total Revenue
Imfinzi Rest of World	1.15 %	of total Revenue
Calquence	5.99 %	of total Revenue
Calquence US	3.98 %	of total Revenue
Calquence Emerging Markets	0.4 %	of total Revenue
Calquence Europe	1.33 %	of total Revenue
Calquence Rest of World	0.28 %	of total Revenue
Lynparza	5.58 %	of total Revenue
Lynparza US	2.44 %	of total Revenue
Lynparza Emerging Markets	1.14 %	of total Revenue
Lynparza Europe	1.56 %	of total Revenue
Lynparza Rest of World	0.45 %	of total Revenue
Enhertu	3.06 %	of total Revenue
Enhertu Emerging Markets	1.14 %	of total Revenue
Enhertu Europe	0.35 %	of total Revenue
Enhertu Rest of World	0.17 %	of total Revenue
Zoladex	1.88 %	of total Revenue
Zoladex US	0.03 %	of total Revenue
Zoladex Emerging Markets	1.43 %	of total Revenue
Zoladex Europe	0.27 %	of total Revenue
Zoladex Rest of World	0.15 %	of total Revenue
Truqap	1.24 %	of total Revenue
Truqap US	1 %	of total Revenue
Truqap Emerging Markets	0.04 %	of total Revenue
Truqap Europe	0.14 %	of total Revenue
Truqap Rest of World	0.06 %	of total Revenue
Imjudo	0.59 %	of total Revenue
Imjudo US	0.39 %	of total Revenue
Imjudo Emerging Markets	0.04 %	of total Revenue
Imjudo Europe	0.09 %	of total Revenue
Imjudo Rest of World	0.08 %	of total Revenue
Datroway	0.13 %	of total Revenue
Datroway Emerging Markets	0 %	of total Revenue
Oncology Others	0.72 %	of total Revenue
Oncology Others US	0.02 %	of total Revenue
Oncology Others Emerging Markets	0.48 %	of total Revenue
Oncology Others Europe	0.03 %	of total Revenue
Oncology Others Rest of World	0.2 %	of total Revenue
CVRM	21.73 %	of total Revenue
CVRM US	4.63 %	of total Revenue
CVRM Emerging Markets	10.03 %	of total Revenue
CVRM Europe	5.78 %	of total Revenue
CVRM Rest of World	1.28 %	of total Revenue
Farxiga	14.3 %	of total Revenue
Farxiga US	2.95 %	of total Revenue
Farxiga Emerging Markets	5.66 %	of total Revenue
Farxiga Europe	5.01 %	of total Revenue
Farxiga Rest of World	0.69 %	of total Revenue
Crestor	2.07 %	of total Revenue
Crestor US	0.08 %	of total Revenue
Crestor Emerging Markets	1.77 %	of total Revenue
Crestor Europe	0 %	of total Revenue
Crestor Rest of World	0.22 %	of total Revenue
Brilinta	1.4 %	of total Revenue
Brilinta US	0.67 %	of total Revenue
Brilinta Emerging Markets	0.46 %	of total Revenue
Brilinta Europe	0.25 %	of total Revenue
Brilinta Rest of World	0.02 %	of total Revenue
Lokelma	1.19 %	of total Revenue
Lokelma US	0.51 %	of total Revenue
Lokelma Emerging Markets	0.22 %	of total Revenue
Lokelma Europe	0.22 %	of total Revenue
Lokelma Rest of World	0.24 %	of total Revenue
Seloken	1.03 %	of total Revenue
Seloken Emerging Markets	1 %	of total Revenue
Seloken Europe	0.03 %	of total Revenue
Seloken Rest of World	0.01 %	of total Revenue
Roxadustat	0.47 %	of total Revenue
Roxadustat Emerging Markets	0.47 %	of total Revenue
Wainua	0.36 %	of total Revenue
Wainua US	0.35 %	of total Revenue
Wainua Emerging Markets	0.01 %	of total Revenue
Wainua Europe	0.01 %	of total Revenue
CVRM Others	0.91 %	of total Revenue
CVRM Others US	0.08 %	of total Revenue
CVRM Others Emerging Markets	0.45 %	of total Revenue
CVRM Others Europe	0.27 %	of total Revenue
CVRM Others Rest of World	0.11 %	of total Revenue
Total Respiratory Immunology	13.9 %	of total Revenue
Total Respiratory Immunology US	6.54 %	of total Revenue
Total Respiratory Immunology Emerging Markets	3.1 %	of total Revenue
Total Respiratory Immunology Europe	2.9 %	of total Revenue
Total Respiratory Immunology Rest of World	1.37 %	of total Revenue
Symbicort	4.91 %	of total Revenue
Symbicort US	2.03 %	of total Revenue
Symbicort Emerging Markets	1.36 %	of total Revenue
Symbicort Europe	0.95 %	of total Revenue
Symbicort Rest of World	0.56 %	of total Revenue
Fasenra	3.37 %	of total Revenue
Fasenra US	2.03 %	of total Revenue
Fasenra Emerging Markets	0.2 %	of total Revenue
Fasenra Europe	0.82 %	of total Revenue
Fasenra Rest of World	0.32 %	of total Revenue
Breztri	2.04 %	of total Revenue
Breztri US	1.05 %	of total Revenue
Breztri Emerging Markets	0.51 %	of total Revenue
Breztri Europe	0.33 %	of total Revenue
Breztri Rest of World	0.16 %	of total Revenue
Tezspire	1.15 %	of total Revenue
Tezspire Emerging Markets	0.07 %	of total Revenue
Tezspire Europe	0.51 %	of total Revenue
Tezspire Rest of World	0.21 %	of total Revenue
Saphnelo	1.17 %	of total Revenue
Saphnelo US	1.01 %	of total Revenue
Saphnelo Emerging Markets	0.03 %	of total Revenue
Saphnelo Europe	0.08 %	of total Revenue
Saphnelo Rest of World	0.04 %	of total Revenue
Pulmicort	0.88 %	of total Revenue
Pulmicort US	0.01 %	of total Revenue
Pulmicort Emerging Markets	0.7 %	of total Revenue
Pulmicort Europe	0.11 %	of total Revenue
Pulmicort Rest of World	0.06 %	of total Revenue
Airsupra	0.28 %	of total Revenue
Airsupra US	0.28 %	of total Revenue
Airsupra Emerging Markets	0.01 %	of total Revenue
Respiratory and immunology Others	0.47 %	of total Revenue
Respiratory and immunology Others US	0.13 %	of total Revenue
Respiratory and immunology Others Emerging Markets	0.23 %	of total Revenue
Respiratory and immunology Others Europe	0.1 %	of total Revenue
Respiratory and immunology Others Rest of World	0.01 %	of total Revenue
Vaccines Immune Therapies	1.44 %	of total Revenue
Vaccines Immune Therapies US	0.36 %	of total Revenue
Vaccines Immune Therapies Emerging Markets	0.37 %	of total Revenue
Vaccines Immune Therapies Europe	0.6 %	of total Revenue
Vaccines Immune Therapies Rest of World	0.11 %	of total Revenue
Beyfortus	0.72 %	of total Revenue
Beyfortus US	0.31 %	of total Revenue
Beyfortus Europe	0.16 %	of total Revenue
Beyfortus Rest of World	0.01 %	of total Revenue
Synagis	0.5 %	of total Revenue
Synagis US	-0.01 %	of total Revenue
Synagis Emerging Markets	0.36 %	of total Revenue
Synagis Europe	0.09 %	of total Revenue
Synagis Rest of World	0.05 %	of total Revenue
FluMist	0.46 %	of total Revenue
FluMist US	0.05 %	of total Revenue
FluMist Emerging Markets	0.01 %	of total Revenue
FluMist Europe	0.36 %	of total Revenue
FluMist Rest of World	0.05 %	of total Revenue
Vaccines Immune Therapies Others	0 %	of total Revenue
Vaccines Immune Therapies Others Emerging Markets	0 %	of total Revenue
Total Rare Disease	15.54 %	of total Revenue
Total Rare Disease US	9.23 %	of total Revenue
Total Rare Disease Emerging Markets	1.77 %	of total Revenue
Total Rare Disease Europe	2.73 %	of total Revenue
Total Rare Disease Rest of World	1.81 %	of total Revenue
Ultomiris	8.03 %	of total Revenue
Ultomiris US	4.54 %	of total Revenue
Ultomiris Emerging Markets	0.44 %	of total Revenue
Ultomiris Europe	1.79 %	of total Revenue
Ultomiris Rest of World	1.25 %	of total Revenue
Soliris	3.13 %	of total Revenue
Soliris US	1.86 %	of total Revenue
Soliris Emerging Markets	0.69 %	of total Revenue
Soliris Europe	0.34 %	of total Revenue
Soliris Rest of World	0.24 %	of total Revenue
Strensiq	2.86 %	of total Revenue
Strensiq US	2.27 %	of total Revenue
Strensiq Emerging Markets	0.18 %	of total Revenue
Strensiq Europe	0.21 %	of total Revenue
Strensiq Rest of World	0.2 %	of total Revenue
Koselugo	1.13 %	of total Revenue
Koselugo US	0.37 %	of total Revenue
Koselugo Emerging Markets	0.39 %	of total Revenue
Koselugo Europe	0.27 %	of total Revenue
Koselugo Rest of World	0.09 %	of total Revenue
Rare Disease Others	0.39 %	of total Revenue
Rare Disease Others US	0.19 %	of total Revenue
Rare Disease Others Emerging Markets	0.07 %	of total Revenue
Rare Disease Others Europe	0.11 %	of total Revenue
Rare Disease Others Rest of World	0.02 %	of total Revenue
Total Other medicines	1.65 %	of total Revenue
Total Other medicines US	0.11 %	of total Revenue
Total Other medicines Emerging Markets	1.25 %	of total Revenue
Total Other medicines Europe	0.14 %	of total Revenue
Total Other medicines Rest of World	0.16 %	of total Revenue
Nexium	1.39 %	of total Revenue
Nexium US	0.11 %	of total Revenue
Nexium Emerging Markets	1.04 %	of total Revenue
Nexium Europe	0.09 %	of total Revenue
Nexium Rest of World	0.15 %	of total Revenue
Other Others	0.27 %	of total Revenue
Other Others US	-0.01 %	of total Revenue
Other Others Emerging Markets	0.21 %	of total Revenue
Other Others Europe	0.06 %	of total Revenue
Other Others Rest of World	0.01 %	of total Revenue
Other royalty income	0.16 %	of total Revenue
Other Alliance Revenue	0.01 %	of total Revenue
Farxiga sales milestones	0.15 %	of total Revenue
Other Collaboration Revenue	0.02 %	of total Revenue
UNITED KINGDOM	1.89 %	of total Revenue
Outside the UK	92.58 %	of total Revenue
Rest of Europe	21.13 %	of total Revenue
FRANCE	2.4 %	of total Revenue
GERMANY	4.92 %	of total Revenue
ITALY	1.84 %	of total Revenue
SPAIN	1.93 %	of total Revenue
SWEDEN	4.47 %	of total Revenue
Others Europe	7.35 %	of total Revenue
The Americas	46.43 %	of total Revenue
CANADA	1.62 %	of total Revenue
Other Americas excluding US and Canada	4.48 %	of total Revenue
Asia Africa And Australasia	25.16 %	of total Revenue
AUSTRALIA	0.77 %	of total Revenue
CHINA	11.3 %	of total Revenue
JAPAN	6.05 %	of total Revenue
Other Asia Africa and Australasia excluding Australia China and Japan	4.63 %	of total Revenue
Customer one	13.99 %	of total Revenue
Customer two	10.14 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Astrazeneca Plc's Comment on Sales, Marketing and Customers

The company supplies products to industry OEMs, tier one suppliers, distributors, and the U.S. Government across Transportation, Industrial, Medical, and Aerospace and Defense sectors. Its major product categories are SENSE (including controls, pedals, piezo sensing products, sensors, switches, and transducers), CONNECT (including EMI/RFI filters, capacitors, frequency control products, resistors, and RF filters), and MOVE (including piezo microactuators and rotary actuators). In 2025, net sales by end market were 43% Transportation, 26% Industrial, 16% Medical, and 15% Aerospace and Defense. Sales and marketing are conducted through sales engineers, independent manufacturers' representatives, and distributors. Sales engineers accounted for approximately 86% of 2025 net sales, distributors about 7%, and independent manufacturers' representatives approximately 7%. Distributors primarily serve smaller customers and provide supply chain fulfillment. Key distribution partners include Avnet, Inc., Digi-Key Electronics, Master Electronics, Future Electronics, and TTI, Inc.

Astrazeneca Plc’s Comment on Sales, Marketing and Customers

AZN's Stock Performance relative to it's Customers

AZN's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Astrazeneca Plc	252,450.44	54,073.00	7,041.00	83,100
SUBTOTAL	0.00	0.00	0.00	-

Sources: Astrazeneca Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Astrazeneca Plc’s corporate clients.
For your research, we’ve provided 9 tables on Astrazeneca Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.